GlassScriptPhysician profile
Richard L Kelly
NPI 1528068178
$3,621.41
in general payments reported to CMS, 2019-2025
25 companies · $60.16 in 2025
The $60.16 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $309 · 2021: $1,365 · 2022: $484 · 2023: $404 · 2024: $45.10 · 2025: $60.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.31 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $873.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $390.39 | 2019 | |
| Abbvie INC. | $352.82 | 2021-2023 | |
| Astellas Pharma US INC | $250.43 | 2019-2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $237.33 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $197.45 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $169.67 | 2019-2023 | |
| Amgen INC. | $163.70 | 2019-2022 | |
| Lilly USA, LLC | $157.94 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $148.75 | 2019-2023 | Ozempic |
| Shockwave Medical, INC | $128.60 | 2022 | |
| Optinose US, INC. | $123.06 | 2020 | |
| Dexcom, INC. | $83.78 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.71 | 2019-2021 | |
| Esperion Therapeutics, INC. | $46.46 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.03 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $28.74 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $24.40 | 2019 | |
| Lifescan, INC. | $24.31 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.17 | 2022 | |
| Almatica Pharma LLC | $21.28 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.21 | 2021 | |
| Eisai INC. | $13.41 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.